ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LUNG vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Pulmonx Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LUNG 3 — JNJ 7
■ METRIC PARITY
options-implied-move
—
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LUNG VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LUNG JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 74.20% 67.90% +6.30 LUNG /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -24.15% 2.97% -27.12 JNJ /fcf-yield <GO>
Operating Margin -59.30% 34.70% -94.00 JNJ /operating-margins <GO>
Net Profit Margin -59.70% 28.50% -88.20 JNJ /net-margins <GO>
Revenue Growth (YoY) 8.00% 6.00% +2.00 LUNG /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.59 -5.39 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 79.1 62.1 +17.00 LUNG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $135.9M $662.49B -$662.36B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LUNG REV JNJ REV LUNG GROSS % JNJ GROSS % LUNG FCF JNJ FCF
FY 2025 $90.5M $94.19B 74.2% 67.9% -$32.8M $19.70B
FY 2024 $83.8M $88.82B 74.0% 69.1% -$33.0M $19.84B
FY 2023 $68.7M $85.16B — — -$37.6M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LUNG // BETA —
JNJ // BETA 1.08